Treos Bio
Latest round
- Series A
Last raised
- Feb 2017
Total raised
- $8M
Investors
- 1
About Treos Bio
Treos Bio Limited, founded in 2013, is based in London, UK, and specializes in developing innovative immunotherapies for cancer.04 mn.Treos Bio specializes in innovative off-the-shelf peptide immunotherapies, utilizing advanced peptide technology known as Promiscuous Epitope (PEPI). The flagship product, PolyPEPI1018, is a multi-peptide immunotherapy designed specifically for colorectal cancer, featuring proprietary peptides that stimulate immune responses against tumor antigens.In the most recent fiscal year of 2023, Treos Bio reported zero revenue, with an EBITDA of USD -4,447,112. This includes applying proprietary data science to match antigens expressed by specific cancers to individual patient genetics, which is aimed at enhancing treatment outcomes. The company is also exploring opportunities to expand into new markets with higher colorectal cancer prevalence, although specific regions and timelines for these expansions have not been disclosed.
Who invested in Treos Bio
1 investor across 1 round
See all investors in Treos Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 13, 2017
Amount
$8M
Investors
Questions about Treos Bio
Who invested in Treos Bio?
Treos Bio has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Treos Bio raised?
Treos Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Treos Bio last raise money?
Treos Bio's most recent round on record is a Series A, in Feb 2017.
What does Treos Bio do?
Treos Bio Limited, founded in 2013, is based in London, UK, and specializes in developing innovative immunotherapies for cancer.
Where is Treos Bio headquartered?
Treos Bio is headquartered in London, UK.
Which VCs invest in companies like Treos Bio?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Treos Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Treos Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.